Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 91 points (0.6%) at 16,492 as of Wednesday, May 7, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,744 issues advancing vs. 1,239 declining with 163 unchanged. The Drugs industry currently sits down 1.7% versus the S&P 500, which is up 0.3%. On the negative front, top decliners within the industry include Perrigo ( PRGO), down 8.4%, Vertex Pharmaceuticals ( VRTX), down 2.5%, Mylan ( MYL), down 2.1%, Alexion Pharmaceuticals ( ALXN), down 1.9% and Regeneron Pharmaceuticals ( REGN), down 1.7%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. AbbVie ( ABBV) is one of the companies pushing the Drugs industry higher today. As of noon trading, AbbVie is up $1.50 (2.9%) to $52.40 on average volume. Thus far, 3.1 million shares of AbbVie exchanged hands as compared to its average daily volume of 6.3 million shares. The stock has ranged in price between $51.27-$52.75 after having opened the day at $52.38 as compared to the previous trading day's close of $50.91. AbbVie Inc., a research-based biopharmaceutical company, is engaged in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. AbbVie has a market cap of $82.0 billion and is part of the health care sector. Shares are down 3.6% year-to-date as of the close of trading on Tuesday. Currently there are 4 analysts who rate AbbVie a buy, no analysts rate it a sell, and 6 rate it a hold. TheStreet Ratings rates AbbVie as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share and increase in stock price during the past year. However, as a counter to these strengths, we find that the growth in the company's net income has been quite unimpressive. Get the full AbbVie Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.